other material
confidence high
sentiment positive
materiality 0.75
FDA clears Sana's IND for SC291 allogeneic CAR T therapy in B-cell malignancies
Sana Biotechnology, Inc.
- SC291 is a CD19-targeted allogeneic CAR T cell therapy using Sana's hypoimmune platform.
- FDA clearance allows first-in-human study in patients with B-cell lymphomas and leukemias.
- Company expects initial clinical data from SC291 study later in 2023.
- Plans to submit a second IND this year for SC262, a CD22-targeted allogeneic CAR T therapy.